Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease

TITLE:

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.

MEDICAL CONTION:

Alzheimer's Disease

AGE:

60 Years to 85 Years

SEX/GENDER:

Male & Female

Overview

Study Details